Career history of Bernard Reculeau
Former positions of Bernard Reculeau
| Companies | Position | Start | End |
|---|---|---|---|
Neurokin SA
 Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Director/Board Member | 2010-10-28 | 2014-03-10 |
Cisbio Bioassays SAS
 Cisbio Bioassays SAS Medical SpecialtiesHealth Technology Cisbio Bioassays SAS develops immunoassays and other related pharmaceutical products. The firm specializes in anti-bodies, vitro diagnostics, and medication for various diseases such as cancer and neurodegenerative disorder. The company was founded in 1986 and is headquartered in Codolet, France. | President | - | 2008-12-31 |
| Rhone-Poulenc Rorer SA | Corporate Officer/Principal | 2011-03-03 | - |
Rhone-Poulenc Rorer, Inc.
 Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA. | Corporate Officer/Principal | - | - |
| Aventis, Inc. | Corporate Officer/Principal | 2011-03-03 | - |
| ION BEAM APPLICATIONS, SA | Corporate Officer/Principal | 2011-03-03 | - |
CIS Bio International SA
 CIS Bio International SA Pharmaceuticals: MajorHealth Technology CIS Bio International SA engages in the distribution of radiopharmaceuticals for diagnosis and therapy. The company is headquartered in Saclay, France. | Chairman | - | - |
| THERATECHNOLOGIES INC. | Director/Board Member | 2004-12-31 | - |
| Independent Dir/Board Member | 2011-10-25 | - |
Training of Bernard Reculeau
| Sciences Po | Undergraduate Degree |
| Ecole Nationale d'Administration | Undergraduate Degree |
Statistics
International
| France | 6 |
| United States | 3 |
| Belgium | 2 |
Operational
| Corporate Officer/Principal | 4 |
| Director/Board Member | 2 |
| Undergraduate Degree | 2 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| ION BEAM APPLICATIONS, SA | Health Technology |
| THERATECHNOLOGIES INC. | Health Technology |
| Private companies | 6 |
|---|---|
| Aventis, Inc. | |
Cisbio Bioassays SAS
Cisbio Bioassays SAS Medical SpecialtiesHealth Technology Cisbio Bioassays SAS develops immunoassays and other related pharmaceutical products. The firm specializes in anti-bodies, vitro diagnostics, and medication for various diseases such as cancer and neurodegenerative disorder. The company was founded in 1986 and is headquartered in Codolet, France. | Health Technology |
Rhone-Poulenc Rorer, Inc.
Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA. | Health Technology |
CIS Bio International SA
CIS Bio International SA Pharmaceuticals: MajorHealth Technology CIS Bio International SA engages in the distribution of radiopharmaceuticals for diagnosis and therapy. The company is headquartered in Saclay, France. | Health Technology |
Neurokin SA
Neurokin SA BiotechnologyHealth Technology Neurokin is a venture-back bio-tech company based in Marseilles, France. Neurokin is specializing in the development of different pharmacological in vitro platforms and in vivo experimental models related to acute neurological diseases. Neurokin's major objective is to identify new CDK inhibitors as neuroprotectants. Neurokin focuses on stroke, epilepsy, cerebral hypoxia after cardiac arrest and traumatic brain injury. As of May 2009, Neurokin has identified new neuroprotective drug candidates and has brought them to the regulatory preclinical stage. | Health Technology |
| Rhone-Poulenc Rorer SA |
- Stock Market
- Insiders
- Bernard Reculeau
- Experience
